Ovarian cancer is the second most lethal gynecological cancer worldwide and while most
patients respond to initial therapy, they often relapse with resistant disease. Human …

Epidermal growth factor receptor (EGFR) inhibitors are a new biologically targeted therapy,
which may offer new hope in the treatment of patients with advanced or recurrent ovarian …

A majority of patients with ovarian carcinoma who receive conventional treatment of surgical
staging and platinum-based chemotherapy recur and ultimately succumb to their diseases …

The epidermal growth factor receptor is overexpressed in up to 60% of ovarian epithelial
malignancies. EGFR regulates complex cellular events due to the large number of ligands …

Advanced ovarian cancer carries a grim prognosis and development of targeted therapies to
improve outcomes has become an active area of research in this disease. The epidermal …

The epithelial growth factor receptor (EGFR) family of receptor tyrosine kinases has been
reported to have an active role in a number of malignancies. Amplifications and …

Ovarian carcinoma is the leading cause of death from gynecologic malignancy in the US.
Factors such as the molecular heterogeneity of ovarian tumors and frequent diagnosis at …

The poor outcome of advanced ovarian cancer under conventional therapy stimulated the
exploration of new strategies to improve therapeutic efficacy. In our preclinical in vitro study …

Despite advances in understanding and treatment, ovarian cancer remains a major cause of
cancer mortality worldwide. Debulking surgery and paclitaxel/carboplatin chemotherapy …

The majority of patients with ovarian cancer, especially those who present with stages IIIC
and IV, will relapse soon after completion of platinum-based induction treatment. It is …